Do you want to read an article? Please log in or register.
Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide
Genitourinary Cancer
Related content
Genitourinary Cancer
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Eur Urol Oncol
Wallis CJD, Ekberg S, Morgans AK, Boegemann M, Paracha N, Gallagher E, Crowther MJ, Shore N
doi: 10.1016/j.euo.2025.03.001
Genitourinary Cancer
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?
Prostate
Shimomura T, Otsuka N, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group
doi: 10.1002/pros.24885
Genitourinary Cancer
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Prostate
Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O
doi: 10.1002/pros.24855
Genitourinary CancerFurther Publications
Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis
Eur J Cancer
Shore N, Morgans AK, Boegemann M, Gallagher E, Paracha N, Serafini P, Pushkarna D, Pourrahmat MM, Kurt M, Abrams KR
doi: 10.1016/j.ejca.2025.115513
Genitourinary Cancer
Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort
Prostate
Shimomura T, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group
doi: 10.1002/pros.24898
Genitourinary Cancer
A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer
Eur Urol
Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA
doi: 10.1016/j.eururo.2024.09.020
COMMENTED
Genitourinary CancerNuclear Medicine
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet Oncol
Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS, UpFrontPSMA Study Team
doi: 10.1016/S1470-2045(24)00440-6
Genitourinary Cancer
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Clin Cancer Res
Hage Chehade C, Graf RP, Ozay ZI, Gebrael G, Sayegh N, Li G, Maughan BL, Antonarakis ES, McKay RR, Agarwal N, Swami U
doi: 10.1158/1078-0432.CCR-25-1178
Genitourinary Cancer
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer
Eur Urol
Fendler WP, Grünwald V, Herrmann K, Hadaschik BA
doi: 10.1016/j.eururo.2024.10.007